Oncologic Confirmatory Trial Accrual Is Part Of FDA-EMEA Agreement
FDA will share information with the European Medicines Agency to ensure that EMEA's new "conditional" approval program will not negatively impact completion of confirmatory trials for products receiving U.S. accelerated approval, Office of Oncology Drug Products Director Richard Pazdur said
You may also be interested in...
Sponsors should develop a strategy to address potential challenges to completion of accelerated approval confirmatory studies in advance of conducting the trials, members of FDA's Oncologic Drugs Advisory Committee suggested Nov. 8
An "exceptional" approval process should be carved out of the accelerated approval program for products targeting rare cancers where there is little likelihood of completing confirmatory trials, members of FDA's Oncologic Drugs Advisory Committee recommended
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011